🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Strides Pharma Science Limited STAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.strides.com
Company Profile ↓
₹1,059.60
+30.45% 1Y
Mkt Cap₹9,766.62 Cr
P/E17.56
P/B2.98
Div. Yield0.50%
52W High₹1,182.56
52W Low₹789.85
Book Value₹337.15
EPS (TTM)₹60.34

Company Overview

Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.3%.

Consistent Profit Growth

Net profit has compounded at 124.8% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 17.6, below the sector median of 41.6.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹4,627.97 Cr (+5.4% YoY); net profit ₹556.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +5.4%, earnings -84.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.7%, profit CAGR 124.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.66%
1 Year:5.38%

Compounded Profit Growth

5 Years:124.83%
1 Year:-84.52%

Stock Price Performance

1 Year:+30.45%
6 Months:+23.09%
3 Months:+4.68%
1 Month:+6.26%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 69% of range
₹789.85 ₹1,182.56
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.81 · Neutral
Price Performance
1M+6.26%
3M+4.68%
6M+23.09%
1Y+30.45%
Valuation vs Sector

P/E of 17.56 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 20.3%.
  • Profit CAGR of 124.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
17.56
Industry PE
41.64
Forward P/E
11.11
PEG Ratio
-
Book Value
₹337.15
Price to Book
2.98
P/S
1.85
EV/EBITDA
13.23
Dividend Yield
0.50%

Growth (CAGR)

Revenue 5Y
8.66%
Profit 5Y
124.83%
Revenue (YoY)
5.38%
Earnings (YoY)
-84.52%

Profitability & Returns

ROCE
20.31%
ROE
17.90%
ROA
8.03%
Profit Margin
12.02%
Op Margin
13.33%
Gross Margin
53.17%
EPS (Latest Qtr)
₹17.02
EPS (TTM)
₹60.34

Balance Sheet & Liquidity

Debt/Equity
0.57
Quick Ratio
0.68
Current Ratio
1.25
Debt
₹1,757.98 Cr
Total Assets
₹6,927.23 Cr
Current Assets
₹3,617.37 Cr
Working Capital
₹721.88 Cr

Ownership

Promoter Holding
30.78%
Chg in Prom Hold
-0.04%
FII / Inst Holding
29.65%
Chg in FII Hold
-0.10%

Financial Snapshot

Enterprise Value
₹9,766.62 Cr
Total Revenue (TTM)
₹4,627.97 Cr
EBITDA
₹1,021.13 Cr
Free Cash Flow
₹284.58 Cr
Operating Cash Flow
₹702.52 Cr
Shares Outstanding
₹9.22 Cr
Gross Margin
53.17%
Payout Ratio
6.01%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 STAR Strides Pharma Science Limited NSEPHARMA 1,059.60 17.56 ₹9,766.62 Cr 0.50% 20.31% 17.90% 8.66% 124.83%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 986.00 Cr930.00 Cr999.00 Cr1,006.00 Cr1,044.00 Cr1,054.00 Cr1,167.00 Cr-1,190.39 Cr1,119.74 Cr1,221.00 Cr1,194.65 Cr1,323.47 Cr1,265.41 Cr
Cost of Revenue --------498.97 Cr444.28 Cr-462.94 Cr536.25 Cr495.19 Cr
Gross Profit --------691.43 Cr675.45 Cr-731.71 Cr787.23 Cr770.22 Cr
Operating Expenses 871.00 Cr796.00 Cr889.00 Cr876.00 Cr874.00 Cr866.00 Cr983.00 Cr-522.42 Cr506.26 Cr990.00 Cr546.38 Cr600.77 Cr596.84 Cr
Operating Income 54.00 Cr74.00 Cr51.00 Cr80.00 Cr121.00 Cr141.00 Cr136.00 Cr-169.01 Cr169.19 Cr181.00 Cr185.32 Cr186.46 Cr173.38 Cr
EBITDA 115.00 Cr134.00 Cr111.00 Cr129.00 Cr169.00 Cr188.00 Cr184.00 Cr-205.56 Cr218.39 Cr231.00 Cr339.48 Cr242.88 Cr296.58 Cr
Interest Expense 81.00 Cr76.00 Cr79.00 Cr70.00 Cr71.00 Cr73.00 Cr74.00 Cr-50.32 Cr47.46 Cr46.00 Cr43.38 Cr41.58 Cr40.56 Cr
Pretax Income -7.00 Cr0-157.00 Cr70.00 Cr23.00 Cr3,369.00 Cr86.00 Cr-106.38 Cr122.04 Cr153.00 Cr245.47 Cr148.05 Cr199.62 Cr
Tax Provision -7.42 Cr07.85 Cr16.10 Cr12.65 Cr33.69 Cr13.76 Cr-20.76 Cr16.45 Cr21.42 Cr37.35 Cr18.77 Cr34.12 Cr
Net Income -14.00 Cr-9.00 Cr-149.00 Cr54.00 Cr10.00 Cr3,350.00 Cr72.00 Cr-82.19 Cr99.61 Cr132.00 Cr202.11 Cr126.94 Cr156.91 Cr
Diluted EPS -1.06-0.79-14.545.401.98364.697.81-8.9210.8113.8421.9213.7717.02

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,196.00 Cr2,861.00 Cr2,755.00 Cr2,845.00 Cr2,178.00 Cr2,752.00 Cr3,316.00 Cr-3,607.67 Cr3,730.02 Cr4,391.68 Cr4,627.97 Cr
Cost of Revenue --------1,745.85 Cr1,883.55 Cr2,133.91 Cr2,167.36 Cr
Gross Profit --------1,861.82 Cr1,846.47 Cr2,257.77 Cr2,460.61 Cr
Operating Expenses 967.00 Cr2,486.00 Cr2,228.00 Cr2,448.00 Cr1,982.00 Cr2,338.00 Cr2,779.00 Cr-1,718.94 Cr1,525.39 Cr1,678.17 Cr1,843.59 Cr
Operating Income 165.00 Cr243.00 Cr401.00 Cr244.00 Cr80.00 Cr240.00 Cr331.00 Cr-142.88 Cr321.08 Cr579.60 Cr617.01 Cr
EBITDA 229.00 Cr374.00 Cr527.00 Cr398.00 Cr197.00 Cr414.00 Cr537.00 Cr-174.64 Cr344.40 Cr886.61 Cr1,021.13 Cr
Interest Expense 47.00 Cr168.00 Cr183.00 Cr196.00 Cr79.00 Cr156.00 Cr150.00 Cr-217.59 Cr238.51 Cr207.43 Cr150.05 Cr
Pretax Income 992.00 Cr137.00 Cr509.00 Cr690.00 Cr303.00 Cr42.00 Cr289.00 Cr--286.20 Cr-114.79 Cr486.92 Cr668.69 Cr
Tax Provision 148.80 Cr42.47 Cr61.08 Cr6.90 Cr-27.27 Cr11.34 Cr31.79 Cr--55.30 Cr29.11 Cr77.52 Cr94.17 Cr
Net Income 844.00 Cr95.00 Cr446.00 Cr684.00 Cr330.00 Cr31.00 Cr258.00 Cr--202.63 Cr-70.61 Cr3,593.45 Cr556.19 Cr
Diluted EPS 141.7812.1544.7174.2536.274.0629.93--22.49-7.76390.5060.34

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 2,475.00 Cr7,410.00 Cr8,046.00 Cr6,585.00 Cr7,807.00 Cr6,131.00 Cr6,969.00 Cr-6,638.42 Cr5,839.76 Cr6,048.73 Cr6,927.23 Cr
Current Assets --------3,245.94 Cr2,972.49 Cr3,101.68 Cr3,617.37 Cr
Cash & Equivalents --------303.50 Cr161.02 Cr112.56 Cr188.70 Cr
Inventory --------1,146.51 Cr1,126.24 Cr1,277.57 Cr1,634.79 Cr
Receivables --------1,299.40 Cr1,141.87 Cr1,202.94 Cr1,288.96 Cr
Total Liabilities --------4,465.54 Cr3,768.05 Cr3,462.26 Cr3,777.89 Cr
Current Liabilities --------2,990.20 Cr2,879.26 Cr2,591.52 Cr2,895.49 Cr
Long Term Debt --------1,139.79 Cr671.50 Cr571.24 Cr552.32 Cr
Total Debt 892.00 Cr3,542.00 Cr3,700.00 Cr2,520.00 Cr3,221.00 Cr2,235.00 Cr2,348.00 Cr-3,029.57 Cr2,516.86 Cr1,879.63 Cr1,757.98 Cr
Total Equity 1,145.00 Cr2,658.00 Cr2,748.00 Cr2,464.00 Cr2,649.00 Cr2,528.00 Cr2,777.00 Cr-2,212.26 Cr2,125.57 Cr2,551.83 Cr3,107.57 Cr
Shares Outstanding --------9.03 Cr9.19 Cr9.22 Cr9.22 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 83.00 Cr73.00 Cr288.00 Cr187.00 Cr60.00 Cr205.00 Cr481.00 Cr-44.41 Cr701.07 Cr684.37 Cr702.52 Cr
Investing Cash Flow 50.00 Cr-2,205.00 Cr-1,222.00 Cr570.00 Cr-145.00 Cr1,321.00 Cr-522.00 Cr-302.47 Cr-150.25 Cr-89.69 Cr-173.04 Cr
Financing Cash Flow -421.00 Cr2,944.00 Cr338.00 Cr-1,016.00 Cr194.00 Cr-1,709.00 Cr-16.00 Cr--213.92 Cr-693.32 Cr-642.58 Cr-453.41 Cr
Capital Expenditure -240.00 Cr-366.00 Cr-674.00 Cr-399.00 Cr-316.00 Cr-147.00 Cr-293.00 Cr--94.94 Cr-118.15 Cr-247.50 Cr-417.94 Cr
Free Cash Flow -157.00 Cr-293.00 Cr-386.00 Cr-212.00 Cr-256.00 Cr58.00 Cr188.00 Cr--50.53 Cr582.91 Cr436.88 Cr284.58 Cr
Net Change in Cash -288.00 Cr812.00 Cr-596.00 Cr-259.00 Cr110.00 Cr-184.00 Cr-56.00 Cr-132.96 Cr-142.51 Cr-47.90 Cr76.07 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------51.6%49.5%51.4%53.2%
Operating Margin % 13.8%8.5%14.6%8.6%3.7%8.7%10.0%-4.0%8.6%13.2%13.3%
Net Margin % 70.6%3.3%16.2%24.0%15.2%1.1%7.8%--5.6%-1.9%81.8%12.0%
ROE % 73.7%3.6%16.2%27.8%12.5%1.2%9.3%--9.2%-3.3%140.8%17.9%
ROCE % --------3.9%10.8%16.8%15.3%

Shareholding Pattern

Insiders
30.78%
Institutions
29.65%
Public Float
42.84%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STAR

Google News Mon, 07 Sep 2026

5-star analyst resets Intel stock price target - thestreet.com

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPSE9ISVdCOGc2Zm05cjVwY3p6cmJ4QU85SVQ0VTN1eVdwaDB4MUFlOTA3VFd5RThURTFZT2RjTTNxN0ltZ1Zwai1DcFdjb0dqM1dQbGVaOWlvblp0UVlZNlY0U0hTUjJhSHZfQkYzdEYzRlpmeFk4d2dmcThyZS1Gd0IzZ3p5ZmVvZTVIWE…

Google News Fri, 04 Sep 2026

Market Wrap: Stocks Little-Changed as Energy and Technology Rise - Morningstar

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPUlRmeHIzNXVtV21NeFI3TWw1ZUh4LVR6NW0xZ1JkWHN1RDVBM0tMQk03Vm5ucUlPNHdlMWlhV3ZaTGg3WllIVFNiN1F4VFczU2c5RFRDTmFVRklLYlljZDNKZ0JDNEpPMTZ2YS1NWnliVzd2N01KblAwblFTYjZhNGp5cmgxZWtMN2pvVE…

Google News hu, 03 Sep 2026

2 Growth Stocks with All-Star Potential and 1 We Question - StockStory

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQldYQko0VWVVRG9EYmY3ZGJ6RjVGRWdVS3RnRVVTbnQxSVRDd1ZNZHVpb3FNNWRUUndaMjlfaTZ1MC1xMVQxOVpGdGJGcnJJZ0ZoWGlUNmlXX0Mwc3ZKcmlBMDdLeDBWdUdFeTZLSXJZdl9RMng2QWM5OGhIbnQxS2p3dzlYNHUxMXRjdm…

Google News Sun, 06 Sep 2026

Non-Independent Director of Blue Star Gold Picks Up 3.8% More Stock - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQTTF6T2xQaTRkZnVZcXpGRkNzTnBER2stRWNLbmx4VkptVFNYN3ExeTBDUHRuQjY0MjB6dWdQYS16Ny1aczZoX3dvVE1Sb3VTV0NHcXEzajkxRlVOaDJ3eEtwWThXZGlycHZiQmZ2VlgzSUdKcGR2a01sSXg5TTZLWmpKQU9xSTNNc1Zjd2…

Google News ue, 01 Sep 2026

GoPro stock is soaring after YouTube star Markiplier buys an 8.5% stake - fastcompany.com

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQZzAtUklLWUM3ZDlqQjBkazFEdHA0ZnJMR2VDQkZqRmRoS0tUMGl4Wkthc3NqZFo4VWtfTGR5MGJpemgxM3FtYnFLYkxncVp1SHlMUXVPTm5Hdmt3Rjlid0ZiVkthRGl2azlZaHpuSVJOQW1zS05QY05zQTIzMTBtQnhQODg5ZlRldjZqXz…

Google News Fri, 04 Sep 2026

5-Star Analyst Resets Intel Stock Price Target on Weaker PC Demand - TradingView

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPSlYzdjVDYkFQUENIZzNLTXZMUFhaTG9heUtLVjBVZllBTTdyaDBySDA5NjVzbERxWVVRSGx0cE9XV3JQMnByVEJBR09pbnlCaE54T1NibEx0YzFtYkdDcmVkRC1rYWFnRlBzcFAxQ0JFS1AwTjRPQ0JzWEVpeVN0S191Zk95elJzRFhpSE…

STAR — Frequently Asked Questions

What is the current share price of Strides Pharma Science Limited (STAR)?

As of 2026-09-08 04:53 IST, Strides Pharma Science Limited (STAR) trades at ₹1,059.60 on NSE. Its 52-week range is ₹789.85 to ₹1,182.56.

What is the market capitalisation of STAR?

Strides Pharma Science Limited (STAR) has a market capitalisation of ₹9,766.62 Cr on NSE.

What is the P/E ratio of STAR?

STAR trades at a trailing price-to-earnings (P/E) ratio of 17.56. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.98.

Does STAR pay a dividend?

Strides Pharma Science Limited (STAR) currently offers a dividend yield of 0.50%.

What is the return on equity (ROE) of STAR?

STAR has a return on equity (ROE) of 17.90%. Its return on capital employed (ROCE) is 20.31%.

Is STAR a good stock to buy?

This page provides a data-driven analysis of Strides Pharma Science Limited (STAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space